AR and prostate carcinoma: Zebularine caused a dose-dependent inhibition of proliferation in both LNCaP and PC3 prostate cancer cells (Figure 5A and 5C, p<0.0001), suggesting that Zebularine has a similar AR-independent growth inhibitory mechanism of action on prostate cancer cells as 5-aza-CdR.